US Edition4 Articles
4 Articles
Transcriptional Regulation by PHGDH Drives Amyloid Pathology in Alzheimer’S Disease
Researchers showed that altered expression of the late-onset Alzheimer’s disease (AD) biomarker phosphoglycerate dehydrogenase (PHGDH) modulates AD pathology in mice and human brain organoids independent of its enzymatic activity. [Cell] Full ArticleGraphical Abstract
The arrival of the Alzheimer's drug Leqembi has great significance for those patients who can benefit from it, according to Jón Snædal, a geriatrician and professor emeritus at the University of Oslo. "This is the first drug that seems to affect the underlying process of the disease. The drugs on the market today primarily address the symptoms that occur, primarily memory loss, and are therefore not sufficiently effective in our opinion. So I th…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
